Pcn292 - Cancer Drugs in Germany: Hta Decisions of New and Innovative Oncology Drugs in Germany – An Analysis Using the Prismaccess® Database

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.374
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Reimbursement Decisions in Oncology Drugs: An International Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

ReDO_DB: The Repurposing Drugs in Oncology Database

ecancermedicalscience
Cancer ResearchOncology
2018English

Pcn305 - Nice and the Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions in Oncology?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy169 - Comparison of Eu5 Market Access Decisions for Crohn’s Disease Based on the Prismaccess® Database

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn314 - Health-Technology Assessments in Oncology: Results of a Review of Decisions in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php43 - Evidence for High Risk Class Medical Devices Versus New Drugs in Germany: What’s the Difference?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy69 - The Burden of Hyperkalemia in Germany – A Claims Database Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Use of Homeopathy in Pediatric Oncology in Germany

Evidence-based Complementary and Alternative Medicine
Alternative MedicineComplementary
2011English

Pmu37 - Introduction Rate of New Hemato-Oncology Drugs in Catalonia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy